Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RT 001

Drug Profile

RT 001

Alternative Names: Di-deuterated ethyl linoleate; Di-deuterated linoleic acid ethyl ester; RT001

Latest Information Update: 26 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Retrotope
  • Developer Parkinsons Institute and Clinical Center; Retrotope
  • Class Antidementias; Antiparkinsonians; Neuroprotectants; Unsaturated fatty acids
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurodegenerative disorders; Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Brain disorders
  • Phase I/II Friedreich's ataxia
  • Clinical Phase Unknown Amyotrophic lateral sclerosis; Neurodegenerative disorders; Progressive supranuclear palsy
  • Preclinical Alzheimer's disease; Huntington's disease; Parkinson's disease

Most Recent Events

  • 05 Nov 2018 Retrotope initiates a phase II/III trial for Infantile neuroaxonal dystrophy (In infants, In children) in USA (PO) (NCT03570931)
  • 04 Oct 2018 Parkinson's Institute and Clinical Center and Retrotope agree to co-develop RT 001 in USA for Progressive supranuclear palsy
  • 04 Oct 2018 Clinical trials in Progressive supranuclear palsy in USA (PO), prior to October 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top